Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in Merkel Cell Carcinoma with Lymph Node Metastases
NCT03271372Phase 3Active, not recruiting
- Sponsor
- University of Washington
- Start
- Dec 2017
- Primary completion
- Jan 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of avelumab in Merkel cell carcinoma (MCC), sponsored by University of Washington. Started Dec 2017; status: active, not recruiting.
02
Drugs
avelumab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT03271372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03271372.